samedan logo
 
 
 
spacer
home > pmps > autumn 2003 > high purity gas generation for use in drug delivery preparation and pharmaceutical manufacturing
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

High Purity Gas Generation for use in Drug Delivery Preparation and Pharmaceutical Manufacturing

The types and uses of process gases in drug delivery preparation and pharmaceutical manufacturing are many and varied. The virtually inert attributes of nitrogen make it suitable for blanketing and purging, while hydrogen, zero-air, TOC-free air, along with nitrogen all find uses within manufacturing process quality laboratories. Today it is possible to generate all of these gases on-site using standalone gas generators.

Applications of High Purity Gases in Drug Delivery and Manufacturing

The diversity of applications for high purity gases within pharmaceutical manufacturing is extremely wide-ranging. It is worthwhile mentioning some of the most common. Blanketing with nitrogen is an important process used to protect volatile substances, which react with oxygen or water vapour. By surrounding the substance with a protective layer of dry, inert gas, the stability of the substance can be maintained without any degradation. Controlled flow may be used to preserve the density of the nitrogen blanket. Purging involves the flushing of a vessel with nitrogen to dispel oxygen and moisture, usually at process start-up or shutdown.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Graham Kerr, Head of R&D, Products of Technology Ltd, and Dr Vic Young, Process Development Manager, Encap Drug Delivery

Dr Graham Kerr joined Products of Technology in 2002 as Head of Research & Development. He has many years of industrial experience in design, manufacturing and product development, having held senior engineering positions at Motorola Manufacturing Systems and Babcock Technology Centre. He holds a PhD in Physics from the University of Glasgow where he spent several years as a Research Associate within the Physics & Astronomy department.


Dr Vic Young graduated from Heriot Watt University with a PhD in Chemistry and started his professional career as an analyst with the Medicines Testing Laboratory in Edinburgh. He joined Encap at its formation in 1989 as QC Manager where he set up the QC lab and then, after several years, changed to become Production Manager for a further six years until taking over his present role of Process Development Manager.


spacer
Dr Graham Kerr
spacer
spacer
spacer
Dr Vic Young
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Catalent Signs Commercial Supply Agreement with Blueprint Medicines Following FDA Approval of GAVRETOT (pralsetinib)

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it had entered into a commercial supply agreement with Blueprint Medicines following FDA approval of GAVRETO™ (pralsetinib). Developed by Blueprint Medicines, GAVRETO is a new therapy indicated for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test.
More info >>

White Papers

Key to Outsourcing Method Development and Validation: A Pragmatic Approach

RSSL

In an industry that is seeing an increasing level of work being outsourced, the Contract Research Organisation (CRO) of choice needs to have proven experience in both the pragmatism and flexibility of the method developer’s mind set and a regulatory background in validation. As companies are focussing on achieving ever shorter times of drug to market, it is vital that a tailored, pragmatic approach is adopted when engaging in both method development and validation activities for an Active Pharmaceutical Ingredient (API) or drug product (DP). Although methods still require a high degree of robustness, the overall strategy should encompass a full evaluation of the regulatory requirements applicable to the particular phase of the drug life-cycle; this is pivotal in Key to Outsourcing Method Development and Validation A Pragmatic Approach order to ensure a successful regulatory submission, where the applicant must demonstrate suitable validation of all methods used to support the filing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement